Replies to post #4890 on Rock Creek Pharmaceuticals Inc. (fka RCPIQ)

[Atlanta1]

well, then it seems that GE's news regarding their imaging agent is potentially great news for Anatabloc. This came out this morning:


General Electric announces final results from a phase 3 study of the investigational PET amyloid imaging agent flutemetamol in terminally ill patients who had agreed to undergo postmortem brain autopsy; Results Show Agreement Between PET Image Reads and Amyloid Levels in Autopsy Studies (19.58 )
Co announced the final results from a phase 3 study of the investigational PET amyloid imaging agent, flutemetamol in terminally ill patients who had agreed to undergo postmortem brain autopsy.1 The data showed strong concordance between flutemetamol PET images and beta amyloid brain histopathology. These data confirm the potential of flutemetamol as an imaging agent to detect beta amyloid plaque, a pathology associated with Alzheimer's disease, in living patients.